Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antihistamine

Therapeutic area intelligence for Antihistamine with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 11
Catalysts: 0
Companies: 5

Companies

Annora Pharma →

Macleods Pharmaceuticals →

Saptalis Pharmaceuticals →

Unique Pharmaceutical Laboratories →

Assets

Levocetirizine →

Recent signals(11)

StrategyAugust 5, 2026

FDA Grants Approval for Fexofenadine Hydrochloride ANDA220413 by Dr. Reddy's

The FDA has granted approval for Dr. Reddy's Abbreviated New Drug Application for Fexofenadine Hydrochloride.

RegulatoryJuly 25, 2026

FDA Approves Supplemental Application for Children's Allegra Hives

The FDA has approved a supplemental application for Children's Allegra Hives, containing fexofenadine hydrochloride.

RegulatoryJuly 21, 2026

Unique Pharmaceutical Laboratories Recalls Cetirizine Hydrochloride Due to Ranitidine Contamination

Unique Pharmaceutical Laboratories is recalling four lots of Cetirizine Hydrochloride Tablets due to cross contamination with Ranitidine.

RegulatoryJuly 19, 2026

FDA Approval for XYZAL ALLERGY 24HR Supplement Application

The FDA has accepted the supplemental application for XYZAL ALLERGY 24HR, indicating a review of its active ingredient, levocetirizine dihydrochloride.

RegulatoryJuly 19, 2026

FDA Approves Supplemental Application for Children's Claritin

The FDA has approved a supplemental application for Children's Claritin (loratadine) submitted by Bayer Healthcare.

RegulatoryJuly 16, 2026

FDA Approves Supplemental Application for Children's Zyrtec Hives

The FDA has approved a supplemental application for Children's Zyrtec Hives, containing cetirizine hydrochloride.

StrategyJuly 16, 2026

FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564

The FDA has granted Abbreviated Approval (AP) status for ANDA205564, a generic formulation of Levocetirizine Dihydrochloride by Macleods Pharmaceuticals.

RegulatoryJune 30, 2026

FDA Approves Supplemental Application for Children's Allegra Hives

The FDA has approved a supplemental application for Children's Allegra Hives, containing fexofenadine hydrochloride.

StrategyJune 24, 2026

FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470

The FDA has granted approval for ANDA219470, a generic version of Diphenhydramine Hydrochloride by Annora Pharma.

StrategyJune 19, 2026

FDA Approves Hydroxyzine Hydrochloride ANDA220271 by Saptalis Pharmaceuticals

The FDA has approved ANDA220271 for Hydroxyzine Hydrochloride submitted by Saptalis Pharmaceuticals.

RegulatoryJune 18, 2026

FDA Approves Supplemental Application for Zyrtec Hives by Kenvue Brands

The FDA has approved a supplemental application for Zyrtec Hives, containing cetirizine hydrochloride.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.